Privo Technologies Launches BeneVet Oncology to Bring Human Cancer Treatment Innovations to Veterinary Medicine
Key Insights
Privo Technologies (search) has established BeneVet Oncology (search), a new subsidiary that will adapt the company's advanced drug delivery platforms from human medicine to address unmet needs in companion animal healthcare.
BeneVet's initial R&D will focus on cutaneous and subcutaneous solid tumors (search) in pets, utilizing Privo's PRV131 intratumoral injectable (search) technology to deliver more precise treatments with fewer side effects.
The new venture will pursue collaborative partnerships with veterinarians, researchers, and animal health organizations to develop clinically effective and practical therapeutic solutions for pets with cancer (search).
Privo Technologies (search) Inc., a phase 3 clinical-stage biopharmaceutical company, announced today the launch of BeneVet Oncology (search), a new subsidiary dedicated to adapting its innovative drug delivery technologies for companion animal health. The Peabody, Massachusetts-based company aims to address significant unmet medical needs in veterinary oncology by leveraging platforms originally developed for human cancer (search) treatment.
BeneVet will focus on developing targeted therapies for pets with cancer (search), applying Privo's expertise in drug delivery systems to create treatments that offer improved efficacy while minimizing side effects.
"Our pets are family members, and they deserve the same level of innovation and care that we dedicate to human health," said Dr. Manijeh Goldberg, CEO and Founder of Privo Technologies (search) Inc. "BeneVet will build on Privo's technological foundation to bring groundbreaking treatments to veterinary medicine, starting with solutions for conditions that currently have limited or inadequate options."
Strategic Focus on Pet Cancer Treatment
BeneVet's initial research and development pipeline will concentrate on two key areas in veterinary oncology:
-
Intratumoral Therapies for Solid Tumors (search): The company plans to adapt Privo's PRV131 intratumoral injectable (search) technology to target tumors in dogs and cats. This approach aims to deliver therapeutic agents directly to tumor sites with greater precision, potentially reducing systemic side effects that often accompany traditional cancer (search) treatments.
-
Topical Treatment of Shallow Tumors: BeneVet is developing sustained-release formulations designed specifically for superficial tumors, with additional applications for chronic pain management in pets.
These initiatives address a significant need in veterinary medicine, as cancer (search) affects approximately 6 million dogs and a similar number of cats annually in the United States alone. Current treatment options for pet cancers often involve adaptations of human protocols that may not be optimized for animal patients.
Collaborative Development Approach
To ensure its products meet real-world clinical needs, BeneVet is establishing partnerships with veterinary oncologists, researchers, and pet owners. This collaborative approach aims to develop solutions that are not only clinically effective but also practical for use in veterinary settings.
"By creating BeneVet, we are reaffirming our commitment to innovation and extending it to improve the lives of our beloved companions," Dr. Goldberg explained. "This new chapter is a natural evolution of our mission to make impactful, science-driven advancements accessible to those who need them most."
The company also plans to pursue strategic collaborations with established animal health organizations to accelerate research initiatives and broaden the impact of its technologies in veterinary medicine.
Bridging Human and Veterinary Medicine
Privo's move into animal health represents a growing trend of cross-pollination between human and veterinary medicine. Advances in one field often benefit the other, with veterinary applications sometimes serving as valuable models for human treatments.
The parent company, Privo Technologies (search), has built its reputation on innovative approaches to drug delivery, particularly in oral cancer (search) treatment. Its proprietary technologies have earned recognition for their potential impact on public health, and the company is currently conducting Phase 3 clinical trials for its lead human products.
BeneVet will operate as a subsidiary while maintaining close technological ties to Privo's research and development infrastructure. This arrangement allows the new venture to benefit from established expertise while focusing specifically on veterinary applications.
The launch of BeneVet Oncology (search) reflects the increasing sophistication of veterinary medicine and pet owners' growing demand for advanced treatment options. As companion animals live longer and become more integrated into family structures, the market for specialized veterinary care continues to expand.
More information about BeneVet's initiatives and development pipeline will be available on the company's website at www.Bene-Vet.com.